Cipher Pharmaceuticals Earnings Date & Estimates

Cipher Pharmaceuticals (OTCMKTS:CPHRF) is a Canadian specialty pharmaceutical company focused primarily on developing, acquiring, and commercializing medicines for dermatology and other areas with unmet medical needs. The company’s business model emphasizes licensing and advancing differentiated prescription products rather than maintaining a broad, traditional drug-discovery operation.

Cipher’s dermatology portfolio has included Epuris, an oral isotretinoin product used to treat severe acne, as well as products for conditions such as actinic keratosis and excessive facial hair. The company has also pursued opportunities to expand its portfolio through product acquisitions, licensing agreements, and regulatory development in selected markets.

Cipher serves healthcare providers and patients primarily in Canada and the United States, with its commercial reach depending on the specific product and applicable regulatory approvals. The company is headquartered in Canada and has historically operated as a commercial-stage pharmaceutical business focused on specialized prescription therapies.